Get the Stockscreener App
17.10
1.00%
0.17
Zenas Biopharma Inc stock is traded at $17.10, with a volume of 231.62K.
It is up +1.00% in the last 24 hours and up +19.50% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$16.93
Open:
$17.23
24h Volume:
231.62K
Relative Volume:
1.38
Market Cap:
$720.09M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.66%
1M Performance:
+19.50%
6M Performance:
+118.39%
1Y Performance:
+0.00%
1-Day Range:
$16.20
$17.70
1-Week Range:
$15.07
$18.24
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
17.10 | 727.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Watch for Bullish Crossover in Zenas BioPharma Inc.July 2025 Levels & Verified Technical Trade Signals - beatles.ru
We Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth Carefully - Yahoo Finance
Will Zenas BioPharma Inc. price bounce be sustainable2025 Dividend Review & Short-Term High Return Ideas - Newser
Is Zenas BioPharma Inc. forming a bottoming baseQuarterly Risk Review & Real-Time Buy Zone Alerts - Newser
Top chart patterns to watch in Zenas BioPharma Inc.2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Measuring Zenas BioPharma Inc.’s beta against major indicesTrade Entry Report & Expert Approved Trade Ideas - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
What makes Zenas BioPharma Inc. stock price move sharply2025 Momentum Check & Consistent Growth Equity Picks - beatles.ru
Is now a turning point for Zenas BioPharma Inc.New Guidance & Intraday High Probability Alerts - Newser
Zenas BioPharma Inc.’s volatility index tracking explainedJuly 2025 Trends & Stepwise Trade Signal Implementation - Newser
Using fundamentals and technicals on Zenas BioPharma Inc.Market Movers & Fast Entry Momentum Trade Alerts - Newser
Zenas BioPharma Inc. recovery potential after sell off2025 Short Interest & Long-Term Growth Portfolio Plans - Newser
Sector ETF performance correlation with Zenas BioPharma Inc.Oil Prices & Consistent Growth Equity Picks - Newser
Analyzing recovery setups for Zenas BioPharma Inc. investorsJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - Newser
What Fibonacci levels say about Zenas BioPharma Inc. rebound2025 Big Picture & Entry Point Confirmation Signals - Newser
Published on: 2025-08-18 02:12:03 - Newser
Is Zenas BioPharma Inc. reversing from oversold territoryMarket Performance Summary & Growth Focused Entry Reports - Newser
Published on: 2025-08-17 15:16:00 - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Reach Out - ACCESS Newswire
Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit - MSN
Heatmap analysis for Zenas BioPharma Inc. and competitorsEarnings Summary Report & Breakout Confirmation Trade Signals - Newser
Analyzing Zenas BioPharma Inc. with multi timeframe chartsMarket Activity Report & Safe Entry Momentum Tips - Newser
What indicators show strength in Zenas BioPharma Inc.Earnings Risk Summary & Weekly High Conviction Trade Ideas - Newser
What moving averages say about Zenas BioPharma Inc.2025 Dividend Review & Safe Capital Investment Plans - Newser
Zenas BioPharma (NASDAQ:ZBIO) Rating Lowered to Sell at Wall Street Zen - Defense World
Zenas BioPharma Q3 EPS Forecast Reduced by HC Wainwright - Defense World
Wedbush Analysts Cut Earnings Estimates for Zenas BioPharma - Defense World
Understanding Zenas BioPharma Inc.’s price movementJuly 2025 Retail & Free Reliable Trade Execution Plans - Newser
Custom watchlist performance reports with Zenas BioPharma Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - Newser
Analyzing net buyer seller activity in Zenas BioPharma Inc.July 2025 Summary & Trade Opportunity Analysis Reports - Newser
When is the best time to exit Zenas BioPharma Inc.Weekly Loss Report & Reliable Intraday Trade Plans - Newser
Is Zenas BioPharma Inc. a Top Dividend Stock to Watch in 2025Wall Street Watch & Verified Momentum Watchlists - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Investigation announced for Investors who hold shares of Zenas - openPR.com
Buy Rating Affirmed for Zenas BioPharma: Promising Developments in Obexelimab Platform Drive Confidence - TipRanks
Zenas BioPharma’s Growth Potential: Key Trials and Strategic Positioning Drive Buy Rating - TipRanks
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Reports Q2 2025 Financial Results - TipRanks
Forecasting Zenas BioPharma Inc. price range with options dataTen-Year Sector Performance and Summary Analysis - Newser
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Zenas Biopharma Inc Stock (ZBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):